The iSeq 100, developed by manufacturer Illumina, was torn down and found to be running an insecure BIOS implementation that opened up the device to malware and ransomware attacks, as well as ...

BIOS/UEFI vulnerabilities in the iSeq 100 DNA sequencer from U.S. biotechnology company Illumina could let attackers disable devices used for detecting illnesses and developing vaccines.

Illumina recently launched the MiSeq i100 and MiSeq i100 Plus Systems, two powerful, compact benchtop sequencers that incorporate more than 140 invention disclosures and 60 patent families.

Currently, Illumina has a market capitalization of $19.82 billion. Buying $100 In ILMN: If an investor had bought $100 of ILMN stock 20 years ago, it would be worth $2,447.88 today based on a ...

The Illumina MiSeq i100 Series, announced last fall, is the company's first customer-installable instrument since the iSeq. Illumina's latest offering was a brand-new challenge for Staff Software ...

The Illumina MiSeq i100 Series, announced last fall, is the company's first customer-installable instrument since the iSeq. Illumina's latest offering was a brand-new challenge for Staff Software ...